Clinical Trial News and Research

RSS

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials.

From Clario 16 Jun 2014

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

16 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months.

13 Jun 2014

2 medications equally effective in treating major epileptic brain seizures in children

A recently published clinical study in the Journal of the American Medical Association has answered an urgent question that long puzzled ER pediatricians: Is the drug lorazepam really safer and more effective than diazepam - the U.S. Food and Drug Administration-approved medication as first line therapy most often used by emergency room doctors to control major epileptic seizures in children?

13 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Cogstate announces signing of first contract for Precision Recruitment tool

Cognition technology company Cogstate is pleased to announce the signing of its first contract for Precision Recruitment, a new web-based tool for streamlining patient recruitment for clinical drug trials.

12 Jun 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

‘Real-world’ ambrisentan data unveiled

The use of and outcomes with ambrisentan in clinical practice are different to those in clinical trials, reflecting different patient characteristics in the “real world”, say researchers.

11 Jun 2014

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer.

11 Jun 2014

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

11 Jun 2014

Children's Hospital Los Angeles ranked among nation's top 5 again

For the third straight year, Children's Hospital Los Angeles is ranked among the top five children's hospitals in the country, a distinction that recognizes the hospital's clinical expertise and the quality and breadth of its patient care.

11 Jun 2014

NSU College of Optometry investigators awarded NIH grant to study convergence insufficiency

The National Eye Institute of the National Institutes of Health has awarded up to $556,532 to investigators at Nova Southeastern University's College of Optometry to study the relationship between the vision condition, convergence insufficiency, and reading performance and attention.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

10 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Auxogyn receives clearance from FDA for Eeva System

Auxogyn, Inc. a leader in women's reproductive health, today announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Clinical Trial News and Research

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

2 medications equally effective in treating major epileptic brain seizures in children

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Cogstate announces signing of first contract for Precision Recruitment tool

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

New research collaboration aims to develop better therapies for autoimmune diseases

‘Real-world’ ambrisentan data unveiled

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Children's Hospital Los Angeles ranked among nation's top 5 again

NSU College of Optometry investigators awarded NIH grant to study convergence insufficiency

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Auxogyn receives clearance from FDA for Eeva System

Celsion signs definitive asset purchase agreement to acquire EGEN

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery